Physician
Oncology
Dr. Frank G. Haluska, MD
Frank Haluska practices Oncology. He went to medical school at Perelman School of Medicine at the University of Pennsylvania. Frank Haluska is a published MD. He has 28 publications published. The most current publication "Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma."
Publications
- Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma.
- Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine DTIC, Plus Interleukin-2 and Interfero...
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias.
- Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects.
- Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in pa...
- Effects of food on the pharmacokinetics of ponatinib in healthy subjects.
- A Multicenter, First-in-Pediatrics, Phase 1, Pharmacokinetic and Pharmacodynamic Study of Ridaforolimus in Patients with Refractory Solid Tumors.
- Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study.
- Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies.
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas.
- Molecular pathogenesis of cutaneous melanocytic neoplasms.
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.
- Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis.
- Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous ...
- Therapeutic targets in melanoma: map kinase pathway.
- Innovations and challenges in melanoma: summary statement from the first Cambridge conference.
- Genetic alterations in signaling pathways in melanoma.
- Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
- Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
- Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
- Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways.
- Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
- Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
- Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G20...
- Phase II study of paclitaxel and carboplatin for malignant melanoma.
- Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanoma.
- Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.
Schools
Perelman School of Medicine University of Pennsylvania
Mass Genl Hospital
Dana Farber Cancer Institute
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Perelman School of Medicine at the University of Pennsylvania